For most biotechs about to turn the profitability corner, launching the first ever treatment for the most common genetic cause of infant mortality might be their biggest headline of the year. But, the launch of Spinraza is just the beginning of a year packed with catalysts for Ionis Pharmaceuticals (NASDAQ: IONS) — and that’s what it’s the one biotech stock I want to own in 2017.
Image source: Getty Images.